Physician profile
Carl E Palffy
NPI 1144228917
$1,135.83
in general payments reported to CMS, 2019-2025
31 companies · $18.49 in 2025
The $18.49 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.27 · 2020: $78.36 · 2021: $247 · 2022: $449 · 2023: $289 · 2024: $34.72 · 2025: $18.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $136.96 | 2022-2023 | Lucemyra, Zimhi |
| Otsuka America Pharmaceutical, INC. | $127.82 | 2022-2025 | Rexulti |
| Abbvie INC. | $91.97 | 2021-2023 | |
| Novo Nordisk INC | $75.33 | 2019-2022 | |
| Lundbeck LLC | $63.63 | 2022 | |
| Orexo US, INC. | $58.69 | 2022-2023 | Zubsolv |
| Indivior INC. | $58.03 | 2022-2023 | Sublocade |
| Alkermes, INC. | $55.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $49.32 | 2021 | |
| Neurocrine Biosciences, INC. | $34.72 | 2024 | Ingrezza |
| Nestle Healthcare Nutrition INC. | $31.81 | 2021 | |
| Amgen INC. | $28.59 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $27.20 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.20 | 2022 | |
| Lilly USA, LLC | $26.25 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.59 | 2020-2021 | |
| Axsome Therapeutics, INC. | $20.43 | 2022 | |
| Antares Pharma, INC. | $18.71 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.84 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.60 | 2022 | |
| Shield Therapeutics INC | $16.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.90 | 2022 | |
| Mylan Specialty L.P. | $15.16 | 2021 | |
| Dexcom, INC. | $14.94 | 2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $14.42 | 2020 | |
| Evoke Pharma, INC. | $14.13 | 2023 | Gimoti |
| Amarin Pharma, INC. | $13.09 | 2020 | |
| Esperion Therapeutics, INC. | $12.81 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.14 | 2021 | |
| Organon LLC | $11.61 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Palffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.